Figure 4 | Scientific Reports

Figure 4

From: Selective targeting of nuclear receptor FXR by avermectin analogues with therapeutic effects on nonalcoholic fatty liver disease

Figure 4

The potency of avermectin analogues in regulating metabolism correlates with their FXR binding capabilities.

(a) Various coactivator motifs bind to FXR in response to 0.5 μM avermectin analogues or GW4064 by AlphaScreen assay. (b) 1 μM compounds induce FXR activity in reporter assays. (c) Dose responses of compounds in inducing FXR to recruit SRC1-2 coregulator binding motif by AlphaScreen assay. (d) Dose response of compounds in inducing the activity of FXR in reporter assays. (e) The recruitment of NCoR-2 to FXR in response to avermectin analogues by AlphaScreen assay. Values are the means ± SEM of three independent experiments.

Back to article page